Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India
Recipharm AB (publ) (“Recipharm” or the “Company”) announces today that it has signed two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.The first acquisition, comprising US[1] and Swedish[2] operations, is expected to close during the second quarter 2016, after review by the Swedish Competition Authority, while the second, comprising operations in India[3] , is conditional on governmental approvals and expected to